Similar articles

• Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

  Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Lanford RE, et al. Science. 2010 Jan 8;327(5962):198-201. doi: 10.1126/science.1178178. Epub 2009 Dec 3. Science. 2010. PMID: 19965718 Free PMC article.
• Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.

  van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW. van der Ree MH, et al. Antiviral Res. 2014 Nov;111:53-9. doi: 10.1016/j.antiviral.2014.08.015. Epub 2014 Sep 8. Antiviral Res. 2014. PMID: 25218783 Clinical Trial.
• The Role of IL28B Genotype in HCV-RNA Baseline Levels.

  Boglione L, Cusato J, Di Perri G, D'Avolio A. Boglione L, et al. Intervirology. 2016;59(2):67-68. doi: 10.1159/000448332. Epub 2016 Sep 8. Intervirology. 2016. PMID: 27603672 No abstract available.
• Hepatitis C Virus Exploitation of Processing Bodies.

  Biegel JM, Pager CT. Biegel JM, et al. J Virol. 2016 Apr 29;90(10):4860-4863. doi: 10.1128/JVI.03056-15. Print 2016 May 15. J Virol. 2016. PMID: 26937026 Free PMC article. Review.
• Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy.

  Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M. Jackowiak P, et al. Curr Pharm Biotechnol. 2011 Nov;12(11):1774-80. doi: 10.2174/138920111798377030. Curr Pharm Biotechnol. 2011. PMID: 21902631 Review.